Thor 707
WebOct 29, 2024 · Sanofi is partnering with Merck to test its THOR-707 compound with Merck’s checkpoint inhibitor Keytruda (pembrolizumab) in solid tumors. THOR-707 is a non-alpha IL-2 candidate that is currently … WebApr 4, 2024 · Alternative Names: IBI-127; Non alpha IL-2 - Sanofi; Non alpha synthorin of IL-2 - Sanofi; SAR-444245; THOR-707 Latest Information Update: 04 Apr 2024. Price : $50 * …
Thor 707
Did you know?
WebApr 9, 2024 · In pre-clinical experiments, THOR-707 exhibited the ability to induce the expansion of CD8+T-cells suggesting potential for anti-tumor effects both as single agent … WebAug 13, 2024 · A Phase 1/2 trial testing the advanced tumors treatment candidate THOR-707 has begun dosing patients in Australia — and has been cleared by the U.S. Food and Drug Administration to enroll participants in the U.S. Australia is the first country recruiting patients for the global HAMMER trial ( NCT04009681 ), with enrollment ongoing in Perth.
WebOct 28, 2024 · Sanofi has been working on this IL-2 candidate since 2024 when it acquired San Diego-based Synthorx for a value of $2.5 billion. The deal gave Sanofi control over … WebApr 12, 2024 · 文章来源：“凯莱英药闻”微信公众号月9日，跨国制药巨头赛诺菲公布旗下工程化il-2药物thor-707（sar444245）中期临床阳性数据。中期临床结果显示，与临床前数据 …
WebBackground SAR444245 (THOR-707) is a recombinant human IL-2 molecule that includes a PEG moiety irreversibly bound to a novel amino acid via click chemistry to block the alpha-binding domain while retaining near-native affinity for the beta/gamma subunits. In animal models, SAR444245 showed anti-tumor benefits, but with no severe side effects, both as … WebApr 12, 2024 · Filip Janku, MD, PhD, MD Anderson Cancer Center, TX, outlines safety and preliminary anti-tumor activity for THOR-707, a recombinant human IL-2 molecule, cur...
WebOct 1, 2024 · THOR-707 is a reprogrammed, site-directed, single pegylated, recombinant human IL-2 (rIL-2) variant that lacks binding affinity for the α chain of the IL-2 receptor. …
WebApr 10, 2024 · This follows its moves on Kymab, Kiadis, Principia and Synthorx, the last done to access the next-generation IL-2 project Thor-707, which at the time had not yielded any … cup online prenotazioni trentoWebAug 9, 2024 · In mice, administration of THOR-707 results in large-scale activation and amplification of CD8 + T cells and NK cells, without Treg expansion characteristic of IL-2. In syngeneic B16-F10 tumor-bearing mice, THOR-707 enhances drug accumulation in the tumor tissue, stimulates tumor-infiltrating CD8 + T and NK cells, and leads to a dose … margoler medicoWebApr 9, 2024 · 这一PEG修饰不但提高IL-2蛋白的稳定性 ，而且让它无法与IL-2受体α结合。这一设计让THOR-707在刺激CD8阳性T细胞和天然杀伤细胞的同时 ，不会同时激发具有免疫抑制功能的Treg的活性。 THOR-707示意图（图片来源：Synthorx公司官网） margolariaWebFilip Janku, MD, PhD, MD Anderson Cancer Center, TX, outlines safety and preliminary anti-tumor activity for THOR-707, a recombinant human IL-2 molecule, cur... cup online prenotazioni lombardiaWebOct 29, 2024 · Sanofi picked up THOR-707 when it acquired Synthorx in December 2024 for $2.5 billion. Synthorx is headquartered in San Diego, California. THOR-707 was the company’s lead immuno-oncology product candidate. Sanofi picked up other earlier-stage cytokine programs in the deal, which was to enhance Sanofi’s oncology and immuno … cup online provincia di trentoWebSanofi bet big on engineered IL-2 in 2024, dropping $2.5 billion to acquire Synthorx and its lead program, THOR-707. Now, the French pharma is reporting early phase 1 data … margo law pontiac ilWebMay 26, 2024 · Conclusions: THOR-707 is a reprogrammed, site-directed, singly-pegylated rIL-2 that changes the pharmacologic profile of IL-2, potentially providing a favorable risk … margo latif